Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Vera

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Brain Pathology (Zurich, Switzerland)|March 5, 2013
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous systemAditya Raghunathan, Khalida Wani, Terri S Armstrong, et al.
Neuro-Oncology Advances|February 29, 2024
Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findingsNicole Briceno, Elizabeth Vera, Edina Komlodi-Pasztor, et al.
Neuro-Oncology Advances|October 27, 2022
Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825Michael E Scheurer, Renke Zhou, Mark R Gilbert, et al.
Neuro-Oncology Practice|September 20, 2022
The Montreal Cognitive Assessment (MoCA) in neuro-oncology: A pilot study of feasibility and utility in telehealth and in-person clinical assessmentsVarna Jammula, James L Rogers, Elizabeth Vera, et al.
Research Square|February 15, 2023
Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trialAmanda L King, Kayla N Roche, Heather E Leeper, et al.
Neuro-Oncology Advances|April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomasShuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Neuro-Oncology|November 16, 2024
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825Joshua D Strauss, Mark R Gilbert, Minesh Mehta, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Journal of Neuro-Oncology|March 8, 2023
Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trialAmanda L King, Kayla N Roche, Heather E Leeper, et al.
Eclinicalmedicine|November 17, 2022
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort studyElizabeth Vera, Alexa Christ, Ewa Grajkowska, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Brain Pathology (Zurich, Switzerland)|March 5, 2013
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous systemAditya Raghunathan, Khalida Wani, Terri S Armstrong, et al.
Neuro-Oncology Advances|February 29, 2024
Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findingsNicole Briceno, Elizabeth Vera, Edina Komlodi-Pasztor, et al.
Neuro-Oncology Advances|October 27, 2022
Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825Michael E Scheurer, Renke Zhou, Mark R Gilbert, et al.
Neuro-Oncology Practice|September 20, 2022
The Montreal Cognitive Assessment (MoCA) in neuro-oncology: A pilot study of feasibility and utility in telehealth and in-person clinical assessmentsVarna Jammula, James L Rogers, Elizabeth Vera, et al.
Research Square|February 15, 2023
Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trialAmanda L King, Kayla N Roche, Heather E Leeper, et al.
Neuro-Oncology Advances|April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomasShuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Neuro-Oncology|November 16, 2024
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825Joshua D Strauss, Mark R Gilbert, Minesh Mehta, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Journal of Neuro-Oncology|March 8, 2023
Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trialAmanda L King, Kayla N Roche, Heather E Leeper, et al.
Eclinicalmedicine|November 17, 2022
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort studyElizabeth Vera, Alexa Christ, Ewa Grajkowska, et al.
Pageof 9